Moheb M. Nasr, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moheb M. Nasr, PhD


Moheb M. Nasr, PhD is a Pharmtech editorial advisory board (EAB) member

Moheb M. Nasr, PhD
Director,
Office of New Drug Quality
Assessment, CDER/FDA

Moheb Nasr is the director of the Office of New Drug Quality Assessment (ONDQA), in the Center for Drug Evaluation and Research (CDER), at the US Food and Drug Administration.  ONDQA is responsible for quality assessments (pre- and postmarketing) of new drugs regulated by CDER. Nasr obtained his PhD degree in Chemistry at the University of Minnesota in Minneapolis.

Nasr holds a BS degree in Pharmacy and a Master’s degree in Pharmaceutical Analysis, both from Cairo University, Egypt.  Nasr joined FDA in 1990, and assumed his current position in June 2003. He is leading the restructuring of the pharmaceutical quality assessment program at FDA. Nasr is a member of FDA’s Council on Pharmaceutical Quality, and is an elected fellow of the American Association of Pharmaceutical Scientists (AAPS).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here